Brooklyn ImmunoTherapeutics Inc. (AMEX: BTX) is 118.53% higher on its value in year-to-date trading and has touched a low of $1.88 and a high of $15.52 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BTX stock was last observed hovering at around $7.69 in the last trading session, with the day’s gains setting it 2.1% off its average median price target of $11.00 for the next 12 months. It is also 11.0% off the consensus price target high of $11.00 offered by 1 analysts, but current levels are 11.0% higher than the price target low of $11.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $9.79, the stock is 72.66% and 35.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.14 million and changing 27.31% at the moment leaves the stock 90.87% off its SMA200. BTX registered 325.65% gain for a year compared to 6-month gain of 127.67%. The firm has a 50-day simple moving average (SMA 50) of $6.30 and a 200-day simple moving average (SMA200) of $5.68.
The stock witnessed a 38.67% loss in the last 1 month and extending the period to 3 months gives it a 91.96%, and is 64.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 24.12% over the week and 21.14% over the month.
Brooklyn ImmunoTherapeutics Inc. (BTX) has around 22 employees, a market worth around $324.54M and $5.80M in sales. Profit margin for the company is -76.40%. Distance from 52-week low is 420.74% and -36.92% from its 52-week high. The company has generated returns on investments over the last 12 months (-217.30%).
Brooklyn ImmunoTherapeutics Inc. (BTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Brooklyn ImmunoTherapeutics Inc. (BTX) is a “Hold”. 1 analysts offering their recommendations for the stock, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
The EPS is expected to shrink by -110.90% this year.
Brooklyn ImmunoTherapeutics Inc. (BTX) Top Institutional Holders
13 institutions hold shares in Brooklyn ImmunoTherapeutics Inc. (BTX), with institutional investors hold 0.20% of the company’s shares. Institutions hold 0.20% of the Float.